The Heart Drug That Worked on Paper but Flopped Where It Counted
AstraZeneca's massive ATTR cardiomyopathy trial just failed, and it's not just one drug's problem. The results are raising billion-dollar questions about whether an entire class of RNA silencing drugs can compete with existing heart therapies.
Imagine you've got a leak in your roof. You hire someone to stop the rain from getting in, but your neighbor already patched most of the holes last week. When the new contractor finishes, the house isn't noticeably drier. Was the contractor bad at their job, or was there just nothing left to fix?
That's essentially what happened in one of the biggest cardiology trials of the year. And it's sending shockwaves through an entire class of drugs worth billions.
The Trial That Shook a Drug Class
AstraZeneca and Ionis Pharmaceuticals just presented the full results of CARDIO-TTRansform at the ESC Congress 2026, with simultaneous publication in the New England Journal of Medicine. The verdict: their drug eplontersen failed to meaningfully help patients with a rare but increasingly diagnosed heart condition called ATTR cardiomyopathy (a disease where a misfolded protein called transthyretin builds up in the heart like plaque in a pipe).
The trial enrolled 1,432 patients across 130 centers in 20 countries. It tracked whether eplontersen could reduce cardiovascular death and recurring heart events over 140 weeks. The answer, in the overall population, was no. The drug group logged 381 primary endpoint events; the placebo group had 392. That's noise, not signal.
But the really interesting part isn't the failure itself. It's why it failed, and what that means for a whole generation of so-called "gene silencing" drugs trying to break into cardiology.
A Fix for a Problem That Was Already Being Fixed
Eplontersen is an antisense oligonucleotide, which is a fancy way of saying it intercepts the genetic instructions your liver uses to make transthyretin. Think of it as erasing the recipe before the bad protein ever gets cooked. In theory, less TTR protein means less toxic buildup in the heart.
The problem? Most patients in the trial were already taking a TTR stabilizer (drugs like tafamidis that don't erase the recipe but instead keep the protein from falling apart and becoming harmful). Tafamidis is the current gold standard for ATTR cardiomyopathy, and it costs roughly per patient.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
$225,000 per year
So when eplontersen was layered on top of stabilizer therapy, the trial was essentially asking: can we get meaningfully better results for patients who are already being treated? The answer was a resounding no. In patients already on a stabilizer, no treatment effect was observed.
That's the leaky roof problem. The stabilizer had already done most of the patching.
The Monotherapy Glimmer
Not everything in the data was bleak. In a prespecified subgroup of patients who were not taking a stabilizer (meaning eplontersen was their only disease-targeting drug), the results looked genuinely promising: a hazard ratio of 0.71, which translates to roughly a 29% reduction in the risk of cardiovascular death and heart events.
That's a meaningful number. But it comes with a giant asterisk. Subgroup analyses are considered "nominally significant," which in clinical trial language means: interesting but not definitive. You can't build a drug approval on a subgroup finding alone. Regulators want to see the whole trial succeed, and this one didn't.
It's like acing the extra credit questions but failing the actual exam. Your teacher (the FDA, in this case) is not going to be impressed.
Why Wall Street Is Nervous About More Than Just Eplontersen
If this were only about one drug from one company, the story would end here. It doesn't, because eplontersen belongs to a broader family of RNA silencing drugs, and the failure raises uncomfortable questions about the entire approach in heart disease.
The basic promise of gene silencing (whether through antisense technology like eplontersen or RNA interference like Alnylam's drugs) is the same: stop the liver from making the troublesome protein. If eplontersen's failure was purely a drug-specific problem, competitors could breathe easy. But the data suggest something more systemic: adding TTR knockdown on top of existing stabilizer therapy may simply not move the needle enough on hard cardiac outcomes.
That's a class-level concern, not a company-level one.
Alnylam: Safe for Now, but Under the Microscope
Alnylam, the biggest pure-play name in gene silencing, has its own dog in this fight: vutrisiran (Amvuttra), which already has FDA approval for ATTR cardiomyopathy based on its HELIOS-B trial. Vutrisiran uses siRNA (a different flavor of gene silencing) rather than antisense technology, but the core mechanism is the same: shut down TTR production at the source.
Alnylam can reasonably argue that its drug is different, its trial was different, and its approval is already in hand. All true. But investor sentiment doesn't always respect those distinctions. When an entire therapeutic thesis gets questioned, everyone in the neighborhood feels it. The billions in projected revenue for TTR-targeting gene silencers now face a higher bar of skepticism.
What This Really Means for the Future
The CARDIO-TTRansform failure doesn't prove that RNA silencing is useless in heart disease. What it does prove is that the incremental benefit of silencing on top of stabilization is smaller than the field hoped, at least in a broad, real-world population of ATTR cardiomyopathy patients.
That leaves the field with a few paths forward. First, gene silencers might find their niche in earlier-stage disease or monotherapy settings, where stabilizers haven't already captured most of the benefit. Second, some experts are now arguing that the real frontier isn't preventing new protein buildup; it's developing drugs that can remove the amyloid deposits already stuck in the heart. That's a fundamentally different (and much harder) problem.
Finally, there's a trial-design lesson buried in here. Heart failure care kept evolving while the study was running. More patients gained access to stabilizers during the trial period, which may have further diluted eplontersen's apparent benefit. Designing a cardiac outcomes trial that stays relevant as standard of care shifts underneath you is like trying to hit a moving target while standing on a treadmill.
The Bottom Line
AstraZeneca's CARDIO-TTRansform trial is a cautionary tale about what happens when a drug works on a biomarker level (eplontersen did slash TTR levels) but can't translate that into outcomes patients and doctors actually care about: living longer and staying out of the hospital.
For the gene-silencing drug class, the message is clear. Success in one disease area (TTR silencers have worked well in nerve disease) doesn't automatically translate to another. The heart, as it turns out, plays by its own rules. And right now, the stabilizers are still winning the game.
4 min read
One Shot to Rewrite Your Cholesterol Forever
CRISPR Therapeutics just showed that a single IV infusion can slash cholesterol and triglycerides for at least a year by permanently editing a gene in liver cells. The one-year Phase 1a data for CTX310 are stunning, but the jump from 15 patients to the real world is where things get interesting.
